Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott On Track To Reach U.S. Drug-Eluting Stent Market By Late 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

Company earns FDA green light for planned 1,670-patient ZOMAXX II randomized trial of ZoMaxx drug-eluting stent. Study will compare ABT-578-eluting TriMaxx-platform stent to Boston Scientific's Taxus.

You may also be interested in...



R&D Roundup, November 2019: LimFlow Starts Pivotal Trial Of Peripheral Shunt; Conservative Coronary Treatment Matches Intervention In Trial

An overview of November’s 10 most-read Medtech Insight articles on topics related to research and development of new medical technology.

Exec Chat: Koa Accel Learns From Past Mistakes To Help Medtech Inventors (Part 2)

Koa Accel CEO Francis Duhay tells Medtech Insight what his company looks for when choosing medtech ideas to support and how his experience as a physician and inventor informs his investment strategy.

Exec Chat: Koa Accel Plans To ‘De-Risk’ Start-Up Investing (Part 1)

Koa Accel CEO Francis Duhay outlines his company’s plans to take some of the risk out of investing in medical device start-ups by supporting inventors with functional expertise. The Irvine, CA-based medical device accelerator is focused on start-ups that will either “fail fast” or earn a 510(k) clearance within 18 months.

Topics

UsernamePublicRestriction

Register

PS061960

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel